Burosumab cleared for x-linked hypophosphatemiaJune 29, 2018
The US Food and Drug Administration approved Crysvita (burosumab) to treat adults and children of ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and development in children and adolescents and problems with bone mineralization throughout a patient’s life.
Clinical studies found 94 percent of adults receiving burosumab once a month achieved normal phosphorus levels compared to 8 percent of those receiving placebo. In children, 94 to 100 percent of patients treated with burosumab every two weeks achieved normal phosphorus levels. In both children and adults, X-ray findings associated with XLH improved with burosumab therapy.